- Home
- FHTX vs PAMT Comparison
FHTX vs PAMT Comparison
Compare FHTX & PAMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- PAMT
- Stock Information
- Founded
- FHTX 2015
- PAMT 1980
- Country
- FHTX United States
- PAMT United States
- Employees
- FHTX N/A
- PAMT N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- PAMT Trucking Freight/Courier Services
- Sector
- FHTX Health Care
- PAMT Industrials
- Exchange
- FHTX Nasdaq
- PAMT Nasdaq
- Market Cap
- FHTX 513.7M
- PAMT 414.1M
- IPO Year
- FHTX 2020
- PAMT 1985
- Fundamental
- Price
- FHTX $7.84
- PAMT $18.70
- Analyst Decision
- FHTX Strong Buy
- PAMT
- Analyst Count
- FHTX 5
- PAMT 0
- Target Price
- FHTX $16.00
- PAMT N/A
- AVG Volume (30 Days)
- FHTX 125.4K
- PAMT 28.8K
- Earning Date
- FHTX 11-04-2024
- PAMT 10-24-2024
- Dividend Yield
- FHTX N/A
- PAMT N/A
- EPS Growth
- FHTX N/A
- PAMT N/A
- EPS
- FHTX N/A
- PAMT N/A
- Revenue
- FHTX $25,515,000.00
- PAMT $728,284,000.00
- Revenue This Year
- FHTX N/A
- PAMT N/A
- Revenue Next Year
- FHTX $8.77
- PAMT N/A
- P/E Ratio
- FHTX N/A
- PAMT N/A
- Revenue Growth
- FHTX N/A
- PAMT N/A
- 52 Week Low
- FHTX $2.70
- PAMT $13.51
- 52 Week High
- FHTX $10.25
- PAMT $23.70
- Technical
- Relative Strength Index (RSI)
- FHTX 44.02
- PAMT N/A
- Support Level
- FHTX $7.33
- PAMT N/A
- Resistance Level
- FHTX $8.25
- PAMT N/A
- Average True Range (ATR)
- FHTX 0.71
- PAMT 0.00
- MACD
- FHTX -0.13
- PAMT 0.00
- Stochastic Oscillator
- FHTX 21.52
- PAMT 0.00
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.